ClinicalTrials.gg
TerminatedNCT02817906Updated Jun 29, 2021Results posted

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

A Phase 3 interventional study of ITI-007 and Placebo in Agitation in Dementia, Including Alzheimer's Disease, sponsored by Intra-Cellular Therapies, Inc.. Terminated at 26 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2021-06-29.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
Pre-specified Interim Analysis Indicated Futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.

02

Conditions studied

  • Agitation in Dementia, Including Alzheimer's Disease
03

In context

Lead sponsor

Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.

First submitted before Intra-Cellular Therapies, Inc. became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of probable Alzheimer's disease
  • symptoms of agitation secondary to probable Alzheimer's disease
  • Able to attend outpatient clinic visits with primary caregiver

Exclusion criteria

Exclusion Criteria:

  • Unable to comply with study procedures
  • Considered medically inappropriate for study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    ITI-007

    9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks.

    Drug: ITI-007

  • Placebo comparator
    Placebo

    Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C)

    The Cohen-Mansfield Agitation Inventory-Community Version is a 37-item scale for identifying and quantifying agitated behaviors in elderly persons in a community setting. Each item is rated from 1='Never' to 7='Several Times Per Hour'. Each category contains a pre-specified subset of the CMAI-C items. The score of each category is the sum of the CMAI-C items included in that category: Aggressive Behavior-Sum of 9 CMAI-C items, ranges from 9 to 63; Non-Aggressive Agitated Behavior-Sum of 6 CMAI-C items, ranges from 6 to 42; Verbally Agitated Behavior-Sum of 4 CMAI-C items, ranges from 4 to 28.

    Time frame: 4 weeks (28 Days)

Secondary outcomes

  1. Change From Baseline in the Clinical Global Impression Scale for Severity of Illness (CGI-S)

    The CGI scale for Severity of Illness is a standardized assessment tool to rate the overall severity of illness and efficacy of medication. CGI-S of Agitation and CGI-S of Aggression will be used in this study as a measure of efficacy. Scores on the CGI-S range from 1 (not ill at all) to 7 (among the most extremely ill).

    Time frame: 4 weeks (28 Days)

07

Results

Posted Jun 29, 2021
Limitations and caveats
CMAI-C Factor Composite score (Aggressive Behavior, Non-Aggressive Agitated Behavior, Verbally Agitated Behavior) was the primary efficacy measure not the CMAI-C Total score.

Participant flow

Participant flow — Overall Study
MilestoneITI-007 9 mgPlacebo
Started8689
Completed7084
Not completed165
Withdrew: Adverse event30
Withdrew: Lack of efficacy10
Withdrew: Protocol violation11
Withdrew: Study terminated by sponsor22
Withdrew: Withdrawal by subject70
Withdrew: Other22

Outcome measures

PrimaryChange From Baseline in the Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C)

The Cohen-Mansfield Agitation Inventory-Community Version is a 37-item scale for identifying and quantifying agitated behaviors in elderly persons in a community setting. Each item is rated from 1='Never' to 7='Several Times Per Hour'. Each category contains a pre-specified subset of the CMAI-C items. The score of each category is the sum of the CMAI-C items included in that category: Aggressive Behavior-Sum of 9 CMAI-C items, ranges from 9 to 63; Non-Aggressive Agitated Behavior-Sum of 6 CMAI-C items, ranges from 6 to 42; Verbally Agitated Behavior-Sum of 4 CMAI-C items, ranges from 4 to 28.

Time frame:
4 weeks (28 Days)
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C)
score on a scale9 mg ITI-007Placebo
Aggressive Agitated Behavior-1.0 ± 0.37-2.3 ± 0.33
Non-Aggressive Agitated Behavior-4.1 ± 0.72-3.9 ± 0.65
Verbally Agitated Behavior-2.9 ± 0.49-2.3 ± 0.45
SecondaryChange From Baseline in the Clinical Global Impression Scale for Severity of Illness (CGI-S)

The CGI scale for Severity of Illness is a standardized assessment tool to rate the overall severity of illness and efficacy of medication. CGI-S of Agitation and CGI-S of Aggression will be used in this study as a measure of efficacy. Scores on the CGI-S range from 1 (not ill at all) to 7 (among the most extremely ill).

Time frame:
4 weeks (28 Days)
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Clinical Global Impression Scale for Severity of Illness (CGI-S)
score on a scale9 mg ITI-007Placebo
CGI-S Aggression-0.4 ± 0.12-0.6 ± 0.10
CGI-S Agitation-0.8 ± 0.11-0.9 ± 0.10

Adverse events

Collected over 4 weeks of double blind treatment.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
9 mg ITI-0070/86 (0%)2/86 (2.3%)13/86 (15.1%)
Placebo0/89 (0%)1/89 (1.1%)8/89 (9%)
Most frequent serious events
Most frequent serious events
Event9 mg ITI-007Placebo
Urinary tract infectionInfections and infestations1/860/89
Ammonia IncreasedInvestigations1/860/89
AcarodermatitisInfections and infestations0/861/89
Most frequent other events
Most frequent other events
Event9 mg ITI-007Placebo
DizzinessNervous system disorders4/860/89
FallInjury, poisoning and procedural complications4/861/89
NauseaGastrointestinal disorders3/860/89
SomnolenceNervous system disorders0/863/89
VomitingGastrointestinal disorders2/860/89
ConstipationGastrointestinal disorders2/860/89
HeadacheNervous system disorders2/861/89
Upper respiratory tract infectionInfections and infestations2/862/89
Abdominal pain upperGastrointestinal disorders0/862/89

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(years)9 mg ITI-007PlaceboTotal
Mean75.6 ± 8.6474.1 ± 8.6174.8 ± 8.63
Sex: Female, Male
Sex: Female, Male(Participants)9 mg ITI-007PlaceboTotal
Female4457101
Male423274
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)9 mg ITI-007PlaceboTotal
White7375148
Black or African American101020
Asian314
Native Hawaiian or Other Pacific Islander011
Multiple011
Unknown011
CMAI-C
CMAI-C(units on a scale)9 mg ITI-007PlaceboTotal
CMAI-C Aggressive Behavior13.28 ± 4.5114.08 ± 5.9213.69 ± 5.27
CMAI-C Non-Aggressive Agitated Behavior17.20 ± 7.4217.46 ± 7.0517.33 ± 7.22
CMAI-C Verbally Agitated Behavior15.37 ± 4.9515.65 ± 5.0215.51 ± 4.98
08

Study locations

26 sites
  • Sun City, Arizona, United States
  • Little Rock, Arkansas, United States
  • Rogers, Arkansas, United States
  • Costa Mesa, California, United States
  • Glendale, California, United States
  • Irvine, California, United States
  • Lemon Grove, California, United States
  • Long Beach, California, United States
  • Oceanside, California, United States
  • Riverside, California, United States
  • Santa Ana, California, United States
  • Hallandale Beach, Florida, United States
  • Hialeah, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Suwanee, Georgia, United States
  • Honolulu, Hawaii, United States
  • Las Vegas, Nevada, United States
  • Berlin, New Jersey, United States
  • Marlton, New Jersey, United States
  • Toms River, New Jersey, United States
  • Brooklyn, New York, United States
  • Staten Island, New York, United States
  • Centerville, Ohio, United States
  • Dayton, Ohio, United States
  • San Antonio, Texas, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Jan 2019, 29 months.

Results were first posted in Jun 2021, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2016
First posted
Jun 29, 2016
StartActual
Aug 29, 2016
Primary completionActual
Jan 30, 2019
CompletionActual
Jan 30, 2019
Results first posted
Jun 29, 2021
Last update
Jun 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02817906
Responsible party
Sponsor
First posted
Jun 29, 2016
Start date
Aug 29, 2016
Primary completion
Jan 30, 2019
Completion
Jan 30, 2019
Results posted
Jun 29, 2021
Last update
Jun 29, 2021

Study contacts

Susan Kozauer, M.D.
study director · Intra-Cellular Therapies, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion